Category Archives: Cancer and neoplasms

Specialty

Kerr et al1 report a study of pathologists who reviewed slides of melanocytic nevi and melanomas. The pathologists were asked to grade the atypia of lesions as low vs high and to distinguish them from invasive melanoma. Seeking to identify pathologist characteristics associated with tumor categorization, the authors found that dermatopathologists were more likely than […]

Jonathan Barratt, MD Credit: IgA Nephropathy Foundation Preliminary findings from the SPARTAN trial assessing the safety and efficacy of sparsentan showed the treatment was safe and well-tolerated as a first-line therapy in patients with newly diagnosed immunoglobulin A nephropathy (IgAN). Data through 12 weeks of treatment in the open-label, single-arm, multi-center, exploratory trial was presented […]

Credit: Fotolia The need for greater focus on racial disparities in health care and health outcomes has become impossible to ignore across all specialties in medicine in recent years. Among patients with kidney disease, long-standing disparities have contributed to increased prevalence and disease-related mortality. These differences have been the focal point of calls from nephrologists […]

Specialty

Specialty

Specialty

Funda Meric-Bernstam, MD New data on fam-trastuzumab deruxtecan-nxki (Enhertu) has maintained clinically meaningful and durable responses in patients with HER2-expressing advanced solid tumors, according to the primary analysis of the ongoing phase 2 DESTINY-PanTumor02 trial (NCT04482309).1 The median progression-free survival was 6.9 months (95% CI, 5.6-8.0) and the median overall survival was 13.4 months (95% […]

The environmental damage caused more than half a century of oil activity in Ecuador’s Amazon are multiplying yearly without effective remediation by the government or the oil companies responsible. To date, there are 1,107 recorded “environmental liabilities” and another 3,568 sites in the Ecuadorian Amazon labeled by the environment ministry as “sources of contamination.” Although […]

Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study Long-Term Safety and Efficacy Data from SIENDO Study in the TP53 Wild-Type Exploratory Subgroup Showed Signals of Improvement in Overall Survival  (OS) Regardless of […]